Skip to content
Head to head

Perrigo vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: PRGO · TAK

Updated 10 minutes ago

1-year performance, rebased to 100

PRGO +25.9%TAK +56.6%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (90); Takeda Pharmaceutical has done best over the past year (+57%); Takeda Pharmaceutical earns the most per share.
PRGOTAK
Snapshot
SectorDrug Manufacturers - Specialty & Generic--
Last price15.9421.77
Change today-0.62%+1.68%
1-year return+39.2%+57.5%
Market cap$2.21B$69.76B
52-week range8.81 – 17.0713.92 – 22.07
Valuation
P/E (TTM)-1.25311.00
P/E percentile, own 5-yr range87th100th
P/B0.911.50
Dividend yield7.28%1.44%
Profitability & growth
EPS (TTM)-10.29-0.30
Net profit (TTM)$-1.43B$-970.94M
Revenue (TTM)$4.09B$4.69T
Provider revenue period date2026-09-252026-09-29
Revenue growth (YoY)-5.2%+6.7%
Gross margin32.3%65.8%
Operating margin4.5%14.3%
Net margin-43.3%0.9%
Free cash flow (TTM)$168.20M$433.95B
Provider cash-flow period date2026-09-252026-09-29
Ownership & sentiment
Institutional ownership119.1%51.3%
Insider activity (12mo)32 buy / 18 sell19 buy / 31 sell
Short interest (% of float)17.7%0.1%
Analyst consensus100% buy (1)100% buy (1)
Analyst price target$19 (+19%)$50 (+132%)
StockVane view
StockVane Quant RatingC (78)C (90)
Company
Employees8,10047,029
Founded20131781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.